Ascelia Pharma Valuation
| ACE Stock | SEK 2.90 0.11 3.65% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Ascelia Pharma AB shows a prevailing Real Value of kr2.77 per share. The current price of the firm is kr2.9. Our model approximates the value of Ascelia Pharma AB from analyzing the firm fundamentals such as return on equity of -0.54, and Current Valuation of 359.6 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Ascelia Pharma's price fluctuation is very risky at this time. Calculation of the real value of Ascelia Pharma AB is based on 3 months time horizon. Increasing Ascelia Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Ascelia Pharma's intrinsic value may or may not be the same as its current market price of 2.90, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.9 | Real 2.77 | Hype 3.01 |
The intrinsic value of Ascelia Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Ascelia Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Ascelia Pharma AB helps investors to forecast how Ascelia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ascelia Pharma more accurately as focusing exclusively on Ascelia Pharma's fundamentals will not take into account other important factors: Ascelia Pharma Total Value Analysis
Ascelia Pharma AB is presently forecasted to have takeover price of 359.6 M with market capitalization of 483.48 M, debt of 553 K, and cash on hands of 219.15 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Ascelia Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
359.6 M | 483.48 M | 553 K | 219.15 M |
Ascelia Pharma Asset Utilization
One of the ways to look at asset utilization of Ascelia is to check how much profit was generated for every dollar of assets it reports. Ascelia Pharma AB shows a negative utilization of assets of -0.33 percent, losing kr0.003347 for each kronor of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each kronor of assets it shows. Put another way, asset utilization of Ascelia Pharma AB shows how unproductive it operates for each kronor spent on its assets.Ascelia Pharma Ownership Allocation
Ascelia Pharma holds a total of 33.67 Million outstanding shares. Ascelia Pharma AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Ascelia Pharma Profitability Analysis
Net Loss for the year was (125.9 M) with profit before overhead, payroll, taxes, and interest of 0.About Ascelia Pharma Valuation
The stock valuation mechanism determines Ascelia Pharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Ascelia Pharma AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Ascelia Pharma. We calculate exposure to Ascelia Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Ascelia Pharma's related companies.Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people.
8 Steps to conduct Ascelia Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Ascelia Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Ascelia Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Ascelia Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Ascelia Pharma's revenue streams: Identify Ascelia Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Ascelia Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Ascelia Pharma's growth potential: Evaluate Ascelia Pharma's management, business model, and growth potential.
- Determine Ascelia Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Ascelia Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.